Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Poximmunomics LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner and 1 distinct art unit. The distribution of work shows a prosecution effort concentrated in a specific technical niche. Practitioners should note that this concentration limits the company's exposure to different examination styles across the USPTO.
The busiest examiner for this portfolio is SIFFORD, JEFFREY MARK, who is responsible for 1 busiest examiner pending office action. This represents the entirety of the company's current pending workload. Because the portfolio relies on the assigned examiner, the outcome of the company's patent strategy is tied to the specific procedural preferences of this individual. The presence of the distinct art unit further defines the nature of the pending application.
For a practitioner, this data indicates a streamlined management process. There is no need to coordinate between multiple examiners or art units, which may simplify the prosecution timeline. However, the lack of diversity in the portfolio means that any delays or specific requirements from SIFFORD, JEFFREY MARK will affect all of the company's active matters. Monitoring the examiner's specific allowance rates and typical response times is essential for forecasting.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560538 | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560538 | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560538 | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines | SIFFORD, JEFFREY MARK | 1671 | §102§103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPoximmunomics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeffrey Mark Sifford has the most, with 1 of Poximmunomics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
